Evolution of systemic therapy of advanced hepatocellular carcinoma.
World J Gastroenterol
; 14(42): 6437-41, 2008 Nov 14.
Article
in En
| MEDLINE
| ID: mdl-19030192
ABSTRACT
Hepatocellular carcinoma (HCC) commonly occurs in hepatitis B endemic areas, especially in Asian countries. HCC is highly refractory to cytotoxic chemotherapy. This resistance is partly related to its tumor biology, pharmacokinetic properties, and both intrinsic and acquired drug resistance. There is no convincing evidence thus far that systemic chemotherapy improves overall survival in advanced HCC patients. Other systemic approaches, such as hormonal therapy and immunotherapy, have also disappointing results. Recently, encouraging results have been shown in using sorafenib in the treatment of advanced HCC patients. In this review, we concisely summarize the evolution of developments in the systemic therapy of advanced HCC.
Full text:
1
Database:
MEDLINE
Therapeutic Methods and Therapies TCIM:
Terapias_biologicas
/
Aromoterapia
Main subject:
Carcinoma, Hepatocellular
/
Liver Neoplasms
/
Antineoplastic Agents
Language:
En
Journal:
World J Gastroenterol
Year:
2008
Type:
Article